A new study indicates that a single course of rituximab reduces inflammatory brain lesions and clinical relapses for as long as 48 weeks in patients with relapsing-remitting multiple sclerosis.
From our partners at VerusMed
verusmed.com
Sponsored by The Doctor’s Channel